Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Isosorbide-5-Mononitrate ER Tablets in Healthy Subjects
NCT03557580Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of isosorbide mononitrate in angina pectoris (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Timepoint and 1 more. Started Apr 2018; status: completed.
02
Drugs
isosorbide mononitrate
03
Conditions
angina pectoris
Beyond the preview
Go deeper on NCT03557580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557580.